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Introduction: Approximately 40- 75% of 
PLHIV in Ukraine are coinfected with HCV, 20-
30% have active form tuberculosis (TB), that 
impairs the course and treatment of HIV 
infection. Despite the free access of ART and 
TB treatment, the number of reported deaths 
due to TB and advanced liver diseases 
continue to rise in PLHIV.  
 
Methods: In study were analyzed clinical data 
of 95 HIV/HCV coinfected patients aged 25-47 
years admitted to Poltava (central region of 
Ukraine) HIV/AIDS clinic in 2003-2014. We 
included 98 patients with known genotype HCV 
and stages of fibrosis in retrospective cohort 
study. Stage of fibrosis is determined with 
transient elastography. We analyzed factors 
contributing to accelerate fibrosis progression 
including socio-demographic and clinical data, 
presence of active forms and MDR TB, 
relapses of TB, adherence to chemoprevention 
of TB. We used Cox proportional hazards 
regression model to outcome measure 
included time from the first positive HCV test to 
diagnosis advanced liver fibrosis (F2-F4). 
 
Results: Accelerated fibrosis progression was 
associated with injection of intravenous drugs 
(HR= 1.4; 95% CI [0.6-2.1]), male sex (HR= 
2.4; 95% CI [1.2-4.5]), lower level of CD4 (HR= 
1.5; 95% CI [1.2-1.9]). At the time of their first 
visit to a health facility, 36% had active form 
TB with relapse in 22%. Presence of TB 
relapses was associated with accelerated 
fibrosis progression (HR= 1.1; 95% CI [0.8-
1.3]). 
 
Conclusions: This study suggests a greater 
risk of accelerated fibrosis progression in 
HIV/HCV coinfected patients with presence of 
relapses of TB. HIV/TB/HCV coinfections 
impair the treatment and prognosis for patients. 
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Introduction: The hemodialysis procedure is a 
risk factor for infections with hepatitis viruses B 
and C. Evaluating the prevalence of viral 
hepatitis B and C impact in patients with 
chronic kidney disease (BCR) on hemodialysis 
may help to prevent the transmission of these 
diseases and can improve the management of 
the hemodialyzed patient. 
 
Material and methods: We studied 4642 
people, aged 23-79 years, divided in two lots: 
group A - 4461 apparently healthy blood 
donors; group B - 181 BCR patients on 
hemodialysis. We detected the immunological 
markers of viral hepatitis B and C by ELISA 
tests and electrochemiluminescence 
performed on COBAS 600 – ROCHE 
DIAGNOSTICS. The hemodialysis patients 
were subjected also to routine biochemical, 
hematological and immunological tests, as 
stated in the management protocol of these 
patients. 
 
Results: In blood donors hepatitis B 
prevalence was 3.07% and hepatitis C 
prevalence 0.65%. In BCR patients prevalence 
of viral hepatitis was 17.13%: 7.18% - hepatitis 
B (OR = 2.65), 8.84% - hepatitis C (OR = 
15.88) and 0.55% had hepatitis B and C co-
infection. Hepatitis prevalence in BCR patients 
was 36.36% in 23-45 years age group. 
